Comparison of oral cephalosporins and their activity against β- lactamase-producing bacteria

Infectious Diseases in Clinical Practice

Volumn 7, Issue SUPPL. 4, 1998, Pages

  Medeiros, Antone A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME STABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; REVIEW;

EID: 0031769907     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199811004-00014     Document Type: Review

References (17)

1. Danziger LH, Pendland SL. Bacterial resistance to β-lactam antibiotics. Am J Health Syst Pharm 1995;52(2 Suppl):3S-8S.
2. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997;24(1 Suppl):19S-45S.
3. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 247-64.
4. Donowitz GR, Mandell GL. β-Lactam antibiotics (first of two parts). N Engl J Med 1988;318:419-26.
5. Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten Ann Pharmacother 1996;30: 258-68.
6. Quintiliani R, Nightingale CH, Freeman CD. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins. Infect Dis Clin Pract 1994,3:1-7
7. Chin NX, Huang HB, Neu HC. Postantibiotic effect of ceftibuten on respiratory pathogens Pediatr Infect Dis J 1995:14(Suppl):84S-87S.
8. Bauernfeind A. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. Diagn Microbiol Infect Dis 1991;14:63-74.
9. Owens RC Jr, Nightingale CH, Nicolau DP. Ceftibuten an overview. Pharmacotherapy 1997;17 707-20.
10. Bauernfeind A. Ceftibuten and bactericidal kinetics: comparative in vitro activity against Enterobacteriaceae producing extended-spectrum β-lactamases. Diagn Microbiol Infect Dis 1991,14:89-92.
11. Medeiros AA. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum β-lactamases have arrived in North America Ann Intern Med 1993;119:428-30.
12. Ghuysen J-M. Molecular structures of penicillin-binding proteins and β-lactamases. Trends Microbiol 1994;2: 372-80.
13. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.
14. Medeiros AA, Crellin J. Comparative susceptibility of clinical isolates producing extended spectrum β-lactamases to ceftibuten: effect of large inocula. Pediatr Infect Dis J 1997;16(Suppl):49S-55S.
15. Medeiros AA, Hare R, Papa E, et al. Gram-negative bacilli resistant to third-generation cephalosporins: β-lactamase characterization and susceptibility to Sch 34343. J Antimicrob Chemother 1985;15(C Suppl) S119-S132.
16. Swenson JM, Ferraro MJ, Jorgensen JH, et al Can different breakpoints be used to detect extended-spectrum β-lactamase (ESBL)-producing organisms? In. Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans (LA). Washington (DC). American Society for Microbiology; 1996 p 64.
17. Jacoby GA, Han P, Alvarez M, et al. Survey of extended-spectrum β-lactamase (ESBL) production in US clinical isolates. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco (CA). Washington (DC): American Society for Microbiology; 1995.